Global Cellular Human Tissue-engineered Skin Substitute market cagr 15.8%

Cellular Human Tissueengineered Skin Substitute Market

Cellular Human Tissue-engineered Skin Substitute

Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031

Request Sample Report

Cellular

Human Tissue-engineered Skin Substitute

Market Size and Growth

The Cellular Human Tissue-engineered Skin Substitute market research reports indicate a growing demand for advanced skin substitutes due to rising prevalence of chronic wounds and skin disorders. The market size for Cellular Human Tissue-engineered Skin Substitutes is projected to reach USD XX million by 2025. Request Sample Report

Companies Covered (Covid 19 Impact Covered)

◍ Allergan (AbbVie)

◍ AlloSource

◍ Organogenesis

◍ BD

◍ Smith & Nephew

◍ Integra LifeSciences

◍ Synthes (Johnson & Johnson)

◍ Axogen

◍ Vericel Corporation

◍ LifeNet Health

◍ MTF Biologics

◍ Arthrex

◍ Wright Medical Group NV (Stryker)

◍ Cook Biotech Incorporated

◍ Aroa Biosurgery

◍ Surgalign Holdings

The cellular human tissue-engineered skin substitute market is highly competitive with key players such as Allergan (AbbVie), AlloSource, Organogenesis, BD, Smith & Nephew, Integra LifeSciences, Synthes (Johnson & Johnson), Axogen, Vericel Corporation, LifeNet Health, MTF Biologics, Arthrex, Wright Medical Group NV (Stryker), Cook Biotech Incorporated, Aroa Biosurgery, and Surgalign Holdings. These companies develop and commercialize advanced skin substitute products, contributing to market growth.

- Allergan (AbbVie) reported sales revenue of $2.3 billion in Q2 2021.

- Smith & Nephew reported sales revenue of $1.4 billion in Q2 2021.

- Integra LifeSciences reported sales revenue of $380 million in Q2 2021.

Market Segmentation

By Application

◍ Hospitals

◍ Specialty Clinics

◍ Wound Care Centers

By Product

◍ Cellular Allogeneic

◍ Cellular Autologous

◍ Others